AP2461A - Antiviral compounds - Google Patents

Antiviral compounds

Info

Publication number
AP2461A
AP2461A AP2007003895A AP2007003895A AP2461A AP 2461 A AP2461 A AP 2461A AP 2007003895 A AP2007003895 A AP 2007003895A AP 2007003895 A AP2007003895 A AP 2007003895A AP 2461 A AP2461 A AP 2461A
Authority
AP
ARIPO
Prior art keywords
antiviral compounds
antiviral
compounds
Prior art date
Application number
AP2007003895A
Other languages
English (en)
Other versions
AP2007003895A0 (en
Inventor
Kleem Chaudhary
Melissa Fleury
Choung U Kim
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2007003895A0 publication Critical patent/AP2007003895A0/xx
Application granted granted Critical
Publication of AP2461A publication Critical patent/AP2461A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2007003895A 2004-07-16 2005-07-18 Antiviral compounds AP2461A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58863304P 2004-07-16 2004-07-16
US59163504P 2004-07-27 2004-07-27
PCT/US2005/025503 WO2006020276A2 (en) 2004-07-16 2005-07-18 Antiviral compounds

Publications (2)

Publication Number Publication Date
AP2007003895A0 AP2007003895A0 (en) 2007-02-28
AP2461A true AP2461A (en) 2012-09-14

Family

ID=35447172

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007003895A AP2461A (en) 2004-07-16 2005-07-18 Antiviral compounds

Country Status (25)

Country Link
US (2) US7642339B2 (xx)
EP (2) EP2316839B1 (xx)
JP (2) JP5676839B2 (xx)
KR (1) KR20070034119A (xx)
AP (1) AP2461A (xx)
AR (1) AR050174A1 (xx)
AT (1) ATE516293T1 (xx)
AU (1) AU2005274700B2 (xx)
BR (1) BRPI0513426A (xx)
CA (1) CA2571984C (xx)
CY (1) CY1112453T1 (xx)
DK (1) DK1778702T3 (xx)
EA (1) EA200700336A1 (xx)
ES (1) ES2468441T3 (xx)
HK (1) HK1103089A1 (xx)
HR (2) HRP20070043A2 (xx)
IL (1) IL180288A0 (xx)
MX (1) MX2007000584A (xx)
NO (1) NO20070866L (xx)
NZ (1) NZ552405A (xx)
PL (2) PL1778702T3 (xx)
PT (1) PT1778702E (xx)
RS (1) RS51974B (xx)
TW (2) TW200614996A (xx)
WO (1) WO2006020276A2 (xx)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
BRPI0613962A2 (pt) * 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK1966130T3 (da) 2005-12-23 2014-02-10 Zealand Pharma As Modificerede lysin-mimetiske forbindelser
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
CN101489564A (zh) * 2006-07-07 2009-07-22 吉里德科学公司 抗病毒的次膦酸酯化合物
EP2043658B1 (en) * 2006-07-07 2012-04-25 Gilead Sciences, Inc. Antiviral phosphinate compounds
AU2013200563C1 (en) * 2006-07-07 2015-05-14 Gilead Sciences, Inc. Antiviral phosphinate compounds
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US20090035271A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
CN101674844A (zh) * 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
KR20090049600A (ko) * 2006-09-13 2009-05-18 노파르티스 아게 마크로시클릭 ｈｃｖ 억제제 및 그의 용도
EP2076278B1 (en) * 2006-10-24 2015-05-06 Merck Sharp & Dohme Corp. Macrocyclic HCV NS3 protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008079266A2 (en) 2006-12-21 2008-07-03 Wyeth Synthesis of pyrrolidine compounds
WO2008086053A1 (en) * 2007-01-03 2008-07-17 Virobay, Inc. Hcv inhibitors
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
KR20090111326A (ko) 2007-02-08 2009-10-26 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 억제 마크로사이클릭 페닐카바메이트
US20080287449A1 (en) * 2007-04-26 2008-11-20 Deqiang Niu Aza-tripeptide hepatitis c serine protease inhibitors
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
AU2008251425A1 (en) 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
AP2874A (en) 2007-06-29 2014-03-31 Gilead Sciences Inc Antiviral compounds
TW200914013A (en) 2007-06-29 2009-04-01 Gilead Sciences Inc Antiviral compounds
AU2014200403B2 (en) * 2007-06-29 2016-05-19 Gilead Sciences, Inc. Antiviral compounds
AR067180A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Compuestos antivirales
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
MX2010005261A (es) 2007-11-14 2010-10-15 Enanta Pharm Inc Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
US8030307B2 (en) * 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
WO2009070692A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
CN101951770B (zh) 2007-12-21 2014-12-31 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
TW201546079A (zh) 2007-12-21 2015-12-16 Celgene Avilomics Res Inc Ｈｃｖ蛋白酶抑制劑及其用途（一）
MX2010008523A (es) 2008-02-04 2010-08-31 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa.
JP5490778B2 (ja) 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
AP2010005416A0 (en) * 2008-04-15 2010-10-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010068760A2 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
KR101546119B1 (ko) 2009-05-13 2015-08-20 길리애드 파마셋 엘엘씨 항바이러스 화합물
KR20100127948A (ko) * 2009-05-27 2010-12-07 한국전자통신연구원 Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US7924650B2 (en) * 2009-06-30 2011-04-12 Oracle America, Inc. Dynamically controlled voltage regulator for a memory
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US8927484B2 (en) * 2009-12-03 2015-01-06 Gilead Sciences, Inc. Antiviral compounds
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
AR083711A1 (es) 2010-11-17 2013-03-20 Gilead Sciences Inc Compuestos heterociclicos utiles en el tratamiento de la hepatitis c
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
ES2629913T3 (es) * 2011-05-19 2017-08-16 Gilead Sciences, Inc. Procesos e intermediarios para la preparación de agentes anti-VIH
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RS54207B1 (en) 2011-11-16 2015-12-31 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
RS55592B1 (sr) 2012-10-19 2017-06-30 Bristol Myers Squibb Co 9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9962251B2 (en) 2013-10-17 2018-05-08 Boston Scientific Scimed, Inc. Devices and methods for delivering implants
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
US11738013B2 (en) 2016-05-27 2023-08-29 Gilead Sciences, Inc. Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
JP6989864B2 (ja) 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
GB2581936B (en) 2017-12-07 2021-02-10 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN110892989B (zh) * 2019-06-27 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解便秘功能的副干酪乳杆菌et-22

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060926A2 (en) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
WO2003064455A2 (en) * 2002-01-30 2003-08-07 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
WO2003064416A1 (en) * 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Heterocyclic tripeptides as hepatitis c inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
IL129407A0 (en) * 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
US6018049A (en) * 1996-12-26 2000-01-25 Shionogi & Co., Ltd. Process for the preparation of carbamoylated imidazole derivatives
ES2241157T3 (es) * 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
YU52303A (sh) * 2001-01-31 2006-05-25 Warner-Lambert Company Postupak karbamoilacije alkohola
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60336550D1 (de) * 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
EP1506000B9 (en) * 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060926A2 (en) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
WO2003064455A2 (en) * 2002-01-30 2003-08-07 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
WO2003064416A1 (en) * 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Heterocyclic tripeptides as hepatitis c inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ORVIETO F ET AL: "Novel, potent phenethylamide inhibitors of the hepatitis C virus (HCV) NS3 protease: Probing the role of P2 aryloxyprolines with hybrid structures" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 13, no. 16, 18 August 2003 (2003-08-18), pages 2745-2748, XP002314396 ISSN: 0960-894X *

Also Published As

Publication number Publication date
MX2007000584A (es) 2007-06-25
JP2012087155A (ja) 2012-05-10
DK1778702T3 (da) 2011-10-17
CA2571984A1 (en) 2006-02-23
EP1778702A2 (en) 2007-05-02
RS51974B (en) 2012-02-29
ES2468441T3 (es) 2014-06-16
JP2008510682A (ja) 2008-04-10
NZ552405A (en) 2011-04-29
EP2316839B1 (en) 2014-03-12
ATE516293T1 (de) 2011-07-15
HRP20070043A2 (en) 2007-07-31
CA2571984C (en) 2012-04-10
PL1778702T3 (pl) 2011-12-30
PL382845A1 (pl) 2008-01-21
HK1103089A1 (en) 2007-12-14
EA200700336A1 (ru) 2009-12-30
EP2316839A1 (en) 2011-05-04
US20080311077A1 (en) 2008-12-18
US20060122123A1 (en) 2006-06-08
PT1778702E (pt) 2011-10-18
JP5767984B2 (ja) 2015-08-26
AR050174A1 (es) 2006-10-04
KR20070034119A (ko) 2007-03-27
US7642339B2 (en) 2010-01-05
AU2005274700A1 (en) 2006-02-23
AP2007003895A0 (en) 2007-02-28
TW200614996A (en) 2006-05-16
WO2006020276A3 (en) 2006-10-05
HRP20110732T1 (hr) 2011-11-30
AU2005274700B2 (en) 2011-11-10
WO2006020276A2 (en) 2006-02-23
EP1778702B1 (en) 2011-07-13
TW201228665A (en) 2012-07-16
BRPI0513426A (pt) 2007-11-27
NO20070866L (no) 2007-04-13
IL180288A0 (en) 2007-06-03
JP5676839B2 (ja) 2015-02-25
CY1112453T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
AP2461A (en) Antiviral compounds
IL180758A0 (en) Antiviral compounds
IL181219A0 (en) Heterocyclic antiviral compounds
IL179534A0 (en) Heterocyclic antiviral compounds
EP1737831A4 (en) NEUROLOGICALLY ACTIVE COMPOUNDS
EP1893629A4 (en) ANTIVIRAL CONNECTIONS
EP1755617A4 (en) PERFLUORCARBON-SOLUBLE COMPOUNDS
GB0405193D0 (en) Compounds
GB0405267D0 (en) Compounds
GB0405101D0 (en) Compounds
GB0401269D0 (en) Compounds
ZA200701118B (en) Antiviral compounds
GB0403593D0 (en) Compounds
GB0403595D0 (en) Compounds
GB0405636D0 (en) Antiviral composition
GB0414327D0 (en) Antiviral composition
GB0413518D0 (en) Antiviral composition
EP1707210A4 (en) ANTIVIRAL PREPARATIONS
GB0403267D0 (en) Compounds
GB0404084D0 (en) Compounds
GB0400696D0 (en) Compounds
GB0400695D0 (en) Compounds
GB0401657D0 (en) Compounds
GB0403594D0 (en) Compounds
GB0401656D0 (en) Compounds